Login to Your Account

Will Dynamics Change for FOBs with Big Pharma in the Mix?

By Donna Young

Monday, March 2, 2009
There is little argument that follow-on biologics (FOBs) legislation to create an FDA approval pathway for the products will make its way through Congress this year, despite what is sure to be a political fight over the number of years of data exclusivity for innovator products.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription